Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: GlobeNewswire
– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and overall survival not yet reached in newly diagnosed NPM1-m patients as of data cutoff – – 65% (31/48) ORR in R/R NPM1-m AML, 83% (19/23) ORR in venetoclax-naïve – – 41% (13/32) ORR in R/R KMT2A-r AML, 70% (7/10) ORR in venetoclax-naïve – – Triplet combination was well tolerated in both newly diagnosed and relapsed/refractory settings; addition of ziftomenib did not increase toxicity beyond that expected with venetoclax/azacitidine alone – – Ziftomenib’s broad clinical development program spans multiple front-line and relapsed/refractory regimens across NPM1-m, FLT3-m and KMT2A-r AML subtypes – – Company-sponsored registrational trials of ziftomenib in front-line AML are ongoing in both intensive chemotherapy-eligible and -ineligible patients – – Kura Oncology to host a virtual investo
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Why The Narrative Around Kura Oncology Is Shifting After Komzifti's FDA Breakthrough [Yahoo! Finance]Yahoo! Finance
- Kura Oncology (NASDAQ:KURA) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Kura Oncology: A Cautious Buy [Seeking Alpha]Seeking Alpha
- Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia [Yahoo! Finance]Yahoo! Finance
- Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid LeukemiaGlobeNewswire
KURA
Earnings
- 11/4/25 - Miss
KURA
Sec Filings
- 12/10/25 - Form 4
- 12/9/25 - Form 144
- 12/2/25 - Form 8-K
- KURA's page on the SEC website